Sonja M McKinlay
Overview
Explore the profile of Sonja M McKinlay including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
1610
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Huynh T, Harty B, Claggett B, Fleg J, McKinlay S, Anand I, et al.
Am J Cardiol
. 2019 Jan;
123(4):611-617.
PMID: 30612727
We aimed to evaluate the impact of diabetes mellitus (DM) and insulin treatment on clinical outcomes in patients with heart failure and preserved left ventricular ejection fraction enrolled in the...
2.
McKinlay S, Brambilla D, Posner J
Am J Hum Biol
. 2017 May;
4(1):37-46.
PMID: 28524413
This paper presents analyses from a comprehensive prospective cohort study of mid-aged women [the Massachusetts Women's Health Study (MWHS)], with numbers sufficient to provide stable estimates of parameters in the...
3.
Data and Safety Monitoring Board evaluation and management of a renal adverse event signal in TOPCAT
Bristow M, Sharma K, Assmann S, Linas S, Gersh B, Grady C, et al.
Eur J Heart Fail
. 2016 Nov;
19(4):457-465.
PMID: 27873428
Clinical trial Data and Safety Monitoring Boards (DSMBs) have a primary obligation of ensuring study participant safety, while maintaining trial integrity. The role of DSMBs is expanding, and ideally should...
4.
Pfeffer M, Claggett B, Assmann S, Boineau R, Anand I, Clausell N, et al.
Circulation
. 2014 Nov;
131(1):34-42.
PMID: 25406305
Background: Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) patients with heart failure and preserved left ventricular ejection fraction assigned to spironolactone did not achieve a...
5.
Shah A, Claggett B, Sweitzer N, Shah S, Anand I, OMeara E, et al.
Circ Heart Fail
. 2014 Aug;
7(5):740-51.
PMID: 25122186
Background: Abnormalities in cardiac structure and function in heart failure with preserved ejection fraction may help identify patients at particularly high risk for cardiovascular morbidity and mortality. Methods And Results:...
6.
Pfeffer M, Pitt B, McKinlay S
N Engl J Med
. 2014 Jul;
371(2):181-2.
PMID: 25006726
No abstract available.
7.
Pitt B, Pfeffer M, Assmann S, Boineau R, Anand I, Claggett B, et al.
N Engl J Med
. 2014 Apr;
370(15):1383-92.
PMID: 24716680
Background: Mineralocorticoid-receptor antagonists improve the prognosis for patients with heart failure and a reduced left ventricular ejection fraction. We evaluated the effects of spironolactone in patients with heart failure and...
8.
Shah A, Shah S, Anand I, Sweitzer N, OMeara E, Heitner J, et al.
Circ Heart Fail
. 2013 Nov;
7(1):104-15.
PMID: 24249049
Background: Heart failure with preserved ejection fraction (HFpEF) is associated with substantial morbidity and mortality. Existing data on cardiac structure and function in HFpEF suggest significant heterogeneity in this population....
9.
Dampier C, Smith W, Wager C, Kim H, Bell M, Miller S, et al.
Clin Trials
. 2013 Mar;
10(2):319-31.
PMID: 23539110
Background: The hallmark of sickle cell disease (SCD) is pain from a vaso-occlusive crisis. Although ambulatory pain accounts for most days in pain, pain is also the most common cause...
10.
Dampier C, Smith W, Kim H, Wager C, Bell M, Minniti C, et al.
Am J Hematol
. 2011 Sep;
86(12):E70-3.
PMID: 21953763
Opioid analgesics administered by patient-controlled analgesia (PCA)are frequently used for pain relief in children and adults with sickle cell disease (SCD) hospitalized for persistent vaso-occlusive pain, but optimum opioid dosing...